Amgen vs Gilead Sciences
AMGN and GILD side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AMGN and GILD compare
Amgen is the larger company, worth 1.2 times as much as Gilead Sciences ($252B against $212B).
Amgen grew revenue faster over the last twelve months (9.1% versus 5.5% for Gilead Sciences).
Amgen keeps more of each dollar of sales as profit, with a net margin of 23.0% compared with −10.6% at Gilead Sciences.
Both pay dividends: Amgen yields 2.1% and Gilead Sciences 1.9%.
Amgen scores higher on the StockData Score (17 against 11 for Gilead Sciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AMGN | GILD |
|---|---|---|
| Size and price | ||
| Market cap | $252B | $212B |
| Share price | $466.01 | $170.68 |
| Change, 1 year | 59.7% | 44.0% |
| Change, 5 years | 118% | 157% |
| Beta (5Y) | 0.42 | 0.44 |
| Employees | 32K | 17K |
| StockData Score | ||
| Total score | 17 (better) | 11 |
| Valuation score | 0 | 0 |
| Growth score | 5 (better) | 2 |
| Performance score | 6 (better) | 3 |
| Health score | 2 | 3 (better) |
| Dividend score | 4 (better) | 3 |
| Valuation | ||
| P/E | 28.9× | – |
| P/S | 6.6× (better) | 6.9× |
| P/B | 21.6× | 17.9× (better) |
| EV/EBITDA | 20.9× | – |
| P/FCF | 24.8× | 16.4× (better) |
| PEG | 5.24 | – |
| FCF yield | 4.0% | 6.1% (better) |
| Fair value | $334.49 | $83.31 |
| Margin of safety | −39.3% (better) | −105% |
| Growth | ||
| Revenue growth (TTM) | 9.1% (better) | 5.5% |
| Revenue growth, 5Y average | 7.6% (better) | 3.6% |
| Net income growth (TTM) | 32.1% (better) | −151% |
| EPS growth (TTM) | 31.6% (better) | −154% |
| EPS growth, 5Y average | 2.9% | 132% (better) |
| Profitability | ||
| Gross margin | 69.5% | 79.6% (better) |
| Operating margin | 30.0% (better) | −8.2% |
| Net margin | 23.0% (better) | −10.6% |
| FCF margin | 26.7% | 42.5% (better) |
| Return on equity | 91.5% (better) | −20.6% |
| Return on invested capital | 17.6% (better) | −5.3% |
| Financial health | ||
| Debt / equity | 4.90 | 2.22 (better) |
| Net debt / EBITDA | 3.07 | – |
| Interest coverage | 4.3× (better) | −2.5× |
| Current ratio | 1.37 (better) | 1.27 |
| Altman Z-score | 2.39 | 3.96 (better) |
| Piotroski F-score | 7 | 8 (better) |
| Dividends and buybacks | ||
| Dividend yield | 2.1% (better) | 1.9% |
| Payout ratio | 60.4% | – |
| Years of dividend growth | 9 | 11 (better) |
| Dividend growth, 5Y average | 8.0% (better) | 3.0% |
| Buyback yield | – | 0.54% |
| Shareholder yield | 2.1% | 2.4% (better) |
| Ownership | ||
| Held by institutions | 82.7% | 89.9% |
| Held by insiders | 0.21% | 0.10% |
| Insider net buying, 12 months | −$29.3M (better) | −$83.5M |
| Short interest, % of float | 2.6% | 1.8% |
Go deeper
- AMGN stock overview
- AMGN income statement
- AMGN valuation and score
- GILD stock overview
- GILD income statement
- GILD valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.